home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2850.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
45 lines
Document 2850
DOCN M94A2850
TI Design and implementation of a community based trial for the comparison
of combination ZDV with ddC or ddI to ZDV monotherapy.
DT 9412
AU Saravolatz L; Winslow D; Stein D; Dehlinger M; Collins G; Deyton L;
Henry Ford Hospital, Detroit, MI 48202.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):210 (abstract no. PB0269). Unique
Identifier : AIDSLINE ICA10/94369725
AB OBJECTIVE: This study compares ZDV alone with ZDV given in combination
with either ddI or ddC with respect to efficacy and safety in HIV
infected patients with CD4 counts of < or = 200 or AIDS in a
community-based setting. METHODS: This randomized, modified double-blind
trial has a target sample size of 1200, based on a 33% reduction in the
primary outcome, progression to AIDS or death over 2 years, with 80%
power for a global significance level of 5%. Data on progression of
disease, survival, toxicity and CD4 counts are being collected for study
endpoints. RESULTS: Fifteen centers enrolled 1,016 patients over 22
months. Overall 43% of the patients are minorities, 22% intravenous drug
users and 7.5% women. At baseline, the mean CD4 was 120, a mean duration
of ZDV use of 12.1 months and 1/2 having had < 6 months of prior ZDV
use. The mean Karnofsky was 91, 32% had previous AIDS defining
opportunistic infections, and 61% were on trimethoprim/sulfamethoxazole.
Results from other antiretroviral trials released during the recruitment
period have not adversely affected patient enrollment or participation.
CONCLUSION: The conduct of antiretroviral trials with clinical endpoints
can be initiated in community-based settings with patient
characteristics more consistent with the demographics of the HIV
epidemic in the U.S. This study will help define the role of
combination-nucleoside therapy in clinical practice in patients with
moderate to advanced HIV infection with differing degrees of prior
antiretroviral therapy.
DE Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL Community
Medicine Comparative Study Didanosine/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS/*THERAPEUTIC USE Double-Blind Method Drug Therapy,
Combination Female Human HIV Infections/*DRUG THERAPY/MORTALITY Male
Research Design Treatment Outcome Zalcitabine/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE Zidovudine/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL MEETING
ABSTRACT MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).